Knockdowns of CD3zeta chain in Primary NK Cells Illustrate Modulation of Antibody-Dependent Cellular Cytotoxicity against Human Immunodeficiency Virus-1.


Journal

AIDS research and human retroviruses
ISSN: 1931-8405
Titre abrégé: AIDS Res Hum Retroviruses
Pays: United States
ID NLM: 8709376

Informations de publication

Date de publication:
23 Jul 2024
Historique:
medline: 23 7 2024
pubmed: 23 7 2024
entrez: 23 7 2024
Statut: aheadofprint

Résumé

Multifaceted natural killer (NK) cell activities are indispensable for controlling human immunodeficiency virus (HIV)-1 transmission and pathogenesis. Among the diverse functions of NK cells, antibody-dependent cellular cytotoxicity (ADCC) has been shown to predict better HIV-1 protection (1-3). ADCC is initiated by the engagement of an Fcg receptor CD16 with an Fc portion of the antibody, leading to phosphorylation of the CD3z chain (CD3) and Fc receptor g chain (FcRg) as well as downstream signaling activation. Though CD3 and FcR were thought to have overlapping roles in NK cell ADCC, several groups have reported that CD3-mediated signals trigger a more robust ADCC (4-8). However, few studies have illustrated the direct contribution of CD3z in HIV-1-specific ADCC. To further understand the roles played by CD3 in HIV-1-specific ADCC, we developed a CD3z knockdown system in primary human NK cells. We observed that HIV-1-specific ADCC was inhibited by CD3z perturbation. In summary, we demonstrated that CD3 is important for eliciting HIV-1-specific ADCC, and this dynamic can be utilized for NK cell immunotherapeutics against HIV-1 infection and other diseases.

Identifiants

pubmed: 39041622
doi: 10.1089/AID.2023.0114
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Sho Sugawara (S)

Duke University, Durham, North Carolina, United States; sho.sugawara@duke.edu.

Esther Lee (E)

Duke University, Durham, North Carolina, United States; esther0204@gmail.com.

Melissa Craemer (M)

Duke University, Durham, North Carolina, United States; craemerm23@students.ecu.edu.

Alayna Pruitt (A)

Duke University, Durham, North Carolina, United States; alayna.pruitt@duke.edu.

Harikrishnan Balachandran (H)

Duke University, DICI, 27 Alexandria Way, Durham, North Carolina, United States, 27708-0187; harikrishnan.balachandran@duke.edu.

Simon Gressens (S)

Duke University, Durham, North Carolina, United States; simon.gressens@duke.edu.

Kyle Kroll (K)

Duke University School of Medicine, Department of Surgery, Durham, North Carolina, United States; kyle.kroll@duke.edu.

Cordelia Manickam (C)

Duke University, 27 alexandria way, Durham, North Carolina, United States, 27708-0187; cordelia.manickam@duke.edu.

Yuxing Li (Y)

University of Maryland School of Medicine, Baltimore, Maryland, United States; yuxingli@umd.edu.

Stephanie Jost (S)

Duke University, Durham, North Carolina, United States; stephanie.jost@duke.edu.

Griffin Woolley (G)

Duke University School of Medicine, Department of Surgery, 27 Alexandria Way, RTP - Reeves Lab, Durham, North Carolina, United States, 27703; griffin.woolley@duke.edu.

R Keith Reeves (RK)

Duke University School of Medicine, Department of Surgery, Director, Division of Innate and Comparative Immunology, DUMC Box 106012, Durham, North Carolina, United States, 27710; kreeves@liebertpub.com.

Classifications MeSH